Brittany Ragon: How Leukemia-Associated Mutations Can Help Shepherd More Personalized AML Therapy
Brittany Ragon, Daniel Peters

Brittany Ragon: How Leukemia-Associated Mutations Can Help Shepherd More Personalized AML Therapy

Brittany Ragon, Associate Professor at Wake Forest University School of Medicine, Director of Hematology Operations at Atrium Health, shared a post on LinkedIn:

“Thrilled to officially welcome Daniel Peters to our Leukemia team by highlighting our recent partnered editorial on the critical work of Meagan Jacoby, Tim Ley, and team, exploring how refined molecular testing (specifically, leukemia-associated mutations = LAMs) can help shepherd more personalized approaches to consolidation therapy in Acute Myeloid Leukemia.

Thanks for the opportunity NEJM Evidence!!”

Title: LAMs Leading Shepherds — MRD-Guided Consolidation in Intermediate-Risk AML

Authors:  Daniel T. Peters, Brittany Knick Ragon

Read the Full Editorial on NEJM Evidence

Brittany Ragon: How Leukemia-Associated Mutations Can Help Shepherd More Personalized AML Therapy